Published in J Steroid Biochem Mol Biol on March 01, 1992
The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res (2008) 2.29
New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res (2011) 2.01
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 1.73
Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol Cell Biol (1999) 1.56
Structural basis for accommodation of nonsteroidal ligands in the androgen receptor. J Biol Chem (2005) 1.54
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One (2015) 1.41
Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol (1999) 1.36
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Evolution of minimal specificity and promiscuity in steroid hormone receptors. PLoS Genet (2012) 1.28
Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One (2011) 1.25
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
Testosterone activates mitogen-activated protein kinase and the cAMP response element binding protein transcription factor in Sertoli cells. Proc Natl Acad Sci U S A (2004) 1.22
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer. J Med Chem (2012) 1.19
Using in vitro high throughput screening assays to identify potential endocrine-disrupting chemicals. Environ Health Perspect (2012) 1.16
Yin Yang 1 regulates the transcriptional activity of androgen receptor. Oncogene (2009) 1.15
Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. J Biol Chem (2011) 1.10
Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate (2009) 1.08
The role of androgen receptor mutations in prostate cancer progression. Curr Genomics (2009) 1.07
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancer. BMC Med Genomics (2010) 1.04
Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J Biomed Sci (2011) 1.03
Selective nucleic acid removal via exclusion (SNARE): capturing mRNA and DNA from a single sample. Anal Chem (2013) 1.02
DHT selectively reverses Smad3-mediated/TGF-beta-induced responses through transcriptional down-regulation of Smad3 in prostate epithelial cells. Mol Endocrinol (2010) 0.99
Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. J Biol Chem (2007) 0.96
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer (2008) 0.95
Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect (2007) 0.95
Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One (2013) 0.94
Inhibitors of vacuolar ATPase proton pumps inhibit human prostate cancer cell invasion and prostate-specific antigen expression and secretion. Int J Cancer (2012) 0.93
An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells. J Cell Sci (2008) 0.93
The impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activity. PLoS One (2012) 0.92
AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther (2013) 0.91
Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res (2009) 0.91
New hormonal therapies for castration-resistant prostate cancer. Endocrinol Metab Clin North Am (2011) 0.90
Cytoskeleton targeting value in prostate cancer treatment. Am J Clin Exp Urol (2014) 0.90
Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer. Neoplasia (2013) 0.89
Growth kinetics of CD133-positive prostate cancer cells. Prostate (2012) 0.89
A competitive inhibitor that reduces recruitment of androgen receptor to androgen-responsive genes. J Biol Chem (2012) 0.88
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Detection of intracellular granularity induction in prostate cancer cell lines by small molecules using the HyperCyt high-throughput flow cytometry system. J Biomol Screen (2009) 0.87
Androgen receptor variation affects prostate cancer progression and drug resistance. Pharmacol Res (2016) 0.87
MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer. Mol Cancer (2011) 0.86
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Hormones and prostate carcinogenesis: Androgens and estrogens. J Carcinog (2011) 0.86
Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol (2005) 0.85
The androgen receptor in hormone-refractory prostate cancer. Asian J Androl (2008) 0.85
Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Mol Endocrinol (2009) 0.84
A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics (2007) 0.84
Androgens and prostate cancer. World J Urol (2003) 0.84
Nuclear targeting of dystroglycan promotes the expression of androgen regulated transcription factors in prostate cancer. Sci Rep (2013) 0.84
Ligand activation of the androgen receptor downregulates E-cadherin-mediated cell adhesion and promotes apoptosis of prostatic cancer cells. Neoplasia (2003) 0.83
3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells. J Nutr (2008) 0.83
Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Mol Cell Endocrinol (2011) 0.83
Structural and functional association of androgen receptor with telomeres in prostate cancer cells. Aging (Albany NY) (2013) 0.83
Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. Br J Cancer (2001) 0.83
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis (2015) 0.81
Inhibition of aberrant androgen receptor induction of prostate specific antigen gene expression, cell proliferation and tumor growth by 17α-estradiol in prostate cancer. J Urol (2011) 0.81
Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells. Assay Drug Dev Technol (2016) 0.80
Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor. BMC Cancer (2002) 0.79
The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells. Mol Cancer (2014) 0.79
Antischistosomal versus antiandrogenic properties of aryl hydantoin Ro 13-3978. Am J Trop Med Hyg (2014) 0.79
CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. Horm Cancer (2016) 0.78
The in vitro and in vivo anti-cancer activities of a standardized quassinoids composition from Eurycoma longifolia on LNCaP human prostate cancer cells. PLoS One (2015) 0.77
Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol (2015) 0.77
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer. PLoS One (2014) 0.77
Fas Activated Serine-Threonine Kinase Domains 2 (FASTKD2) mediates apoptosis of breast and prostate cancer cells through its novel FAST2 domain. BMC Cancer (2014) 0.77
Androgen Receptor-Mediated Growth Suppression of HPr-1AR and PC3-Lenti-AR Prostate Epithelial Cells. PLoS One (2015) 0.76
Cell-based assays for screening androgen receptor ligands. Semin Reprod Med (2015) 0.76
Molecular and biochemical effects of a kola nut extract on androgen receptor-mediated pathways. J Toxicol (2008) 0.75
Discovery Proteomics Identifies a Molecular Link between the Coatomer Protein Complex I and Androgen Receptor-dependent Transcription. J Biol Chem (2016) 0.75
Nonsteroidal androgen receptor ligands: versatile syntheses and biological data. ACS Med Chem Lett (2012) 0.75
Growth of LAPC4 prostate cancer xenograft tumor is insensitive to 5α-reductase inhibitor dutasteride. Am J Clin Exp Urol (2014) 0.75
Advances in genetics: widening our understanding of prostate cancer. F1000Res (2016) 0.75
Methylselenocysteine preventing castration-resistant progression of prostate cancer. Prostate (2015) 0.75
Androgen receptor sequence and variations in several common prostate cancer cell lines. Cancer Biol Ther (2010) 0.75
Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. Oncotarget (2016) 0.75
The cholesterol metabolite 27-hydroxycholesterol stimulates cell proliferation via ERβ in prostate cancer cells. Cancer Cell Int (2017) 0.75
Inhibition of Androgen Receptor Nuclear Localization and Castration Resistant Prostate Tumor Growth by Pyrroloimidazole-Based Small Molecules. Mol Cancer Ther (2017) 0.75
Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science (1997) 6.60
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature (1997) 6.15
A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun (1990) 3.79
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res (1994) 3.43
Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res (1997) 3.37
Acute leukaemia in bcr/abl transgenic mice. Nature (1990) 2.93
Heterogeneity in polyadenylation cleavage sites in mammalian mRNA sequences: implications for SAGE analysis. Nucleic Acids Res (2001) 2.72
Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol (1991) 2.54
Potent inhibition of estrogen sulfotransferase by hydroxylated PCB metabolites: a novel pathway explaining the estrogenic activity of PCBs. Endocrinology (2000) 2.50
A polymorphism in the glucocorticoid receptor gene may be associated with and increased sensitivity to glucocorticoids in vivo. J Clin Endocrinol Metab (1998) 2.45
Ribosomal precursor particles from yeast. Exp Cell Res (1975) 2.41
Role of co-activators and co-repressors in the mechanism of steroid/thyroid receptor action. Recent Prog Horm Res (1997) 2.41
Toporegulation of bacterial division according to the nucleoid occlusion model. Res Microbiol (1991) 2.23
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res (1998) 2.10
Inactivating mutations in the gene for thyroid oxidase 2 (THOX2) and congenital hypothyroidism. N Engl J Med (2002) 2.07
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem (1996) 2.05
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
Targeted disruption of the Insl3 gene causes bilateral cryptorchidism. Mol Endocrinol (1999) 1.99
Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol (1994) 1.94
Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Mol Endocrinol (1997) 1.90
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol (1997) 1.85
Role of the nucleoid in the toporegulation of division. Res Microbiol (1990) 1.81
Androgen receptors in endocrine-therapy-resistant human prostate cancer. Int J Cancer (1991) 1.81
Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J Natl Cancer Inst (2000) 1.78
A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab Invest (1997) 1.74
Maturation of ribosomes in yeast. I Kinetic analysis by labelling of high molecular weight rRNA species. Biochim Biophys Acta (1976) 1.74
The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol (1991) 1.72
Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene (2011) 1.71
Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol (1999) 1.68
Lack of association between five polymorphisms in the human glucocorticoid receptor gene and glucocorticoid resistance. Hum Genet (1997) 1.66
Cloning, structure and expression of a cDNA encoding the human androgen receptor. Biochem Biophys Res Commun (1988) 1.64
The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem (1989) 1.58
Nuclear import of the human androgen receptor. Biochem J (1993) 1.58
Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun (1982) 1.44
Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry (1992) 1.44
Importance of the content and localization of tyrosine residues for thyroxine formation within the N-terminal part of human thyroglobulin. Eur J Endocrinol (1995) 1.42
The PTEN gene in locally progressive prostate cancer is preferentially inactivated by bi-allelic gene deletion. J Pathol (2006) 1.40
Combinatorial association and abundance of components of interferon-stimulated gene factor 3 dictate the selectivity of interferon responses. Proc Natl Acad Sci U S A (1995) 1.40
The N-terminal domain of the human androgen receptor is encoded by one, large exon. Mol Cell Endocrinol (1989) 1.38
Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ Res (1998) 1.36
Trinucleotide repeat polymorphism in the androgen receptor gene (AR). Nucleic Acids Res (1992) 1.34
Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology (1997) 1.34
Co-occurrence based meta-analysis of scientific texts: retrieving biological relationships between genes. Bioinformatics (2005) 1.33
The interferon-stimulated gene 54 K promoter contains two adjacent functional interferon-stimulated response elements of different strength, which act synergistically for maximal interferon-alpha inducibility. Eur J Biochem (1994) 1.33
Two frequent missense mutations in Pendred syndrome. Hum Mol Genet (1998) 1.31
Substitution of aspartic acid-686 by histidine or asparagine in the human androgen receptor leads to a functionally inactive protein with altered hormone-binding characteristics. Mol Endocrinol (1991) 1.27
Discovery and characterization of endometrial epithelial messenger ribonucleic acids using the ovine uterine gland knockout model. Endocrinology (1999) 1.26
Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2). Mol Endocrinol (1998) 1.26
Differential distribution and regulation of estrogen receptor-alpha and -beta mRNA within the female rat brain. Brain Res Mol Brain Res (1998) 1.24
Organization, structure and expression of murine interferon alpha genes. Nucleic Acids Res (1985) 1.24
Epitope prediction and confirmation for the human androgen receptor: generation of monoclonal antibodies for multi-assay performance following the synthetic peptide strategy. Biochim Biophys Acta (1991) 1.24
Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry (1997) 1.24
Androgen receptor expression in human tissues: an immunohistochemical study. J Histochem Cytochem (1991) 1.20
Estrogen receptor-beta mRNA expression in rat ovary: down-regulation by gonadotropins. Mol Endocrinol (1997) 1.20
Structure, chromosome localization, and regulation of expression of the interferon-regulated mouse Ifi54/Ifi56 gene family. Genomics (1994) 1.19
Metabolism of red-cell lipids. I. Incorporation in vitro of fatty acids into phospholipids from mature erythrocytes. Biochim Biophys Acta (1965) 1.18
Localization of androgen receptors in human skin by immunohistochemistry: implications for the hormonal regulation of hair growth, sebaceous glands and sweat glands. J Endocrinol (1992) 1.18
17Beta-hydroxysteroid dehydrogenase-3 deficiency: diagnosis, phenotypic variability, population genetics, and worldwide distribution of ancient and de novo mutations. J Clin Endocrinol Metab (1999) 1.16
Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. Urol Res (1990) 1.14
Characterization of an expanded glutamine repeat androgen receptor in a neuronal cell culture system. Neurobiol Dis (1997) 1.13
Expression of estrogen receptor alpha and beta during mouse embryogenesis. Mech Dev (1999) 1.13
A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans. Mol Endocrinol (1997) 1.12
Involvement of FtsZ in coupling of nucleoid separation with septation. Mol Microbiol (1992) 1.11
Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Cancer Res (1997) 1.11
Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer (1988) 1.10
Aberrant splicing of androgen receptor mRNA results in synthesis of a nonfunctional receptor protein in a patient with androgen insensitivity. Proc Natl Acad Sci U S A (1990) 1.10
High-affinity binding of oestradiol-17beta by cytosols from testis interstitial tissue, pituitary, adrenal, liver and accessory sex glands of the male rat. Biochem J (1974) 1.09